Skip to main content
Journal cover image

Bayesian meta-analysis of phase 3 results of aducanumab, lecanemab, donanemab, and high-dose gantenerumab in prodromal and mild Alzheimer's disease

Publication ,  Journal Article
Teipel, SJ; Temp, AGM; Lutz, MW
Published in: Alzheimer's and Dementia: Translational Research and Clinical Interventions
January 1, 2024

INTRODUCTION: Phase 3 trials using the anti-amyloid antibodies aducanumab, lecanemab, donanemab, and high-dose gantenerumab in prodromal and mild Alzheimer's disease dementia were heterogeneous in respect to statistical significance of effects. However, heterogeneity of results has not yet directly be quantified. METHODS: We used Bayesian random effects meta-analysis to quantify evidence for or against a treatment effect, and assessed the size of the effect and its heterogeneity. Data were extracted from published studies where available and Web based data reports, assuming a Gaussian data generation process. RESULTS: We found moderate evidence in favor of a treatment effect (Bayes factor = 13.2). The effect was moderate to small with −0.33 (95% credible interval −0.54 to −0.10) points on the Clinical Dementia Rating – Sum of Boxes (CDR-SB) scale. The heterogeneity parameter was low to moderate with 0.21 (0.04 to 0.45) CDR-SB points. DISCUSSION: Heterogeneity across studies was moderate despite some trials reaching statistical significance, while others did not. This suggests that the negative aducanumab and gantenerumab trials are in full agreement with the expected effect sizes.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Alzheimer's and Dementia: Translational Research and Clinical Interventions

DOI

EISSN

2352-8737

Publication Date

January 1, 2024

Volume

10

Issue

1

Related Subject Headings

  • 5202 Biological psychology
  • 3209 Neurosciences
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Teipel, S. J., Temp, A. G. M., & Lutz, M. W. (2024). Bayesian meta-analysis of phase 3 results of aducanumab, lecanemab, donanemab, and high-dose gantenerumab in prodromal and mild Alzheimer's disease. Alzheimer’s and Dementia: Translational Research and Clinical Interventions, 10(1). https://doi.org/10.1002/trc2.12454
Teipel, S. J., A. G. M. Temp, and M. W. Lutz. “Bayesian meta-analysis of phase 3 results of aducanumab, lecanemab, donanemab, and high-dose gantenerumab in prodromal and mild Alzheimer's disease.” Alzheimer’s and Dementia: Translational Research and Clinical Interventions 10, no. 1 (January 1, 2024). https://doi.org/10.1002/trc2.12454.
Teipel SJ, Temp AGM, Lutz MW. Bayesian meta-analysis of phase 3 results of aducanumab, lecanemab, donanemab, and high-dose gantenerumab in prodromal and mild Alzheimer's disease. Alzheimer’s and Dementia: Translational Research and Clinical Interventions. 2024 Jan 1;10(1).
Teipel, S. J., et al. “Bayesian meta-analysis of phase 3 results of aducanumab, lecanemab, donanemab, and high-dose gantenerumab in prodromal and mild Alzheimer's disease.” Alzheimer’s and Dementia: Translational Research and Clinical Interventions, vol. 10, no. 1, Jan. 2024. Scopus, doi:10.1002/trc2.12454.
Teipel SJ, Temp AGM, Lutz MW. Bayesian meta-analysis of phase 3 results of aducanumab, lecanemab, donanemab, and high-dose gantenerumab in prodromal and mild Alzheimer's disease. Alzheimer’s and Dementia: Translational Research and Clinical Interventions. 2024 Jan 1;10(1).
Journal cover image

Published In

Alzheimer's and Dementia: Translational Research and Clinical Interventions

DOI

EISSN

2352-8737

Publication Date

January 1, 2024

Volume

10

Issue

1

Related Subject Headings

  • 5202 Biological psychology
  • 3209 Neurosciences
  • 3202 Clinical sciences